Ind-Swift Laboratories Ltd. Announces Incorporation Under Regulation 30 Regarding Incorporation of ISLL Middle East L.L.C-FZ
wholly owned subsidiary to be considered as Related Party. The initial investment in the said wholly owned subsidiary would be a Related Party Transaction and said investment made by the
Company shall be on Arms' Length basis. The Company is the Promoter of the said wholly owned subsidiary. Save and except as mentioned above, the Company is not interested in any other manner. Industry to which the entity being acquired belongs: Pharmaceuticals (Newly incorporated, yet to commence business operations). The WOS intends to strategically invest in
pharmaceutical and allied activities. This includes exploring potential acquisitions, tie-ups, or joint ventures. Additionally, the Company aims to establish and operate pharmaceutical manufacturing units. Nature of consideration - whether cash consideration or share swap and details of the same: Subscription to 100% of the equity in WOS, to be paid in cash. Date of Incorporation: 17-May-2024. Regd. Office: Meydan Grandstand, 6th floor, Meydan Road, Nad Al Sheba, Dubai, U.A.E History /Turnover: Not Applicable (Newly incorporated).